Inventor · Narberth, PA, US

John Scholler

22Patents
8h-index
16Co-inventors
72Inventor score

Filing activity: Jun 20, 2000 → Aug 5, 2021

Most-cited inventions

PatentTitleAreaCited byStatus
US9394368B2 Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor Chemistry; Metallurgy 94 Active
US9573988B2 Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells Chemistry; Metallurgy 70 Active
US9365641B2 Compositions and methods for targeting stromal cells for the treatment of cancer Chemistry; Metallurgy 42 Active
US9714278B2 Use of ICOS-based CARs to enhance antitumor activity and CAR persistence Chemistry; Metallurgy 30 Active
US6565856B1 Compounds and methods for treatment and diagnosis of chlamydial infection Chemistry; Metallurgy 26 Expired
US10040846B2 Compositions and methods for generating a persisting population of T cells useful for the treatment of cancer Chemistry; Metallurgy 21 Active
US9783591B2 Use of the CD2 signaling domain in second-generation chimeric antigen receptors Chemistry; Metallurgy 20 Active
US10221245B2 Treatment of cancer using humanized anti-CD19 chimeric antigen receptor Chemistry; Metallurgy 14 Active
US10927184B2 Treatment of cancer using humanized anti-CD19 chimeric antigen receptor Chemistry; Metallurgy 5 Active
US10501519B2 Use of the CD2 signaling domain in second-generation chimeric antigen receptors Chemistry; Metallurgy 3 Active
US11299536B2 Compositions and methods for generating a persisting population of T cells useful for the treatment of cancer Chemistry; Metallurgy 3 Active
US10308717B2 Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor Chemistry; Metallurgy 2 Active
US11597754B2 Use of the CD2 signaling domain in second-generation chimeric antigen receptors Chemistry; Metallurgy 2 Active
US10800840B2 Compositions and methods for generating a persisting population of T cells useful for the treatment of cancer Chemistry; Metallurgy 2 Active
US10577407B2 Use of ICOS-based CARS to enhance antitumor activity and CAR persistence Chemistry; Metallurgy 1 Active
US11028177B2 Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells Chemistry; Metallurgy 1 Active
US11865167B2 Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor Chemistry; Metallurgy 1 Active
US10329355B2 Compositions and methods for targeting stromal cells for the treatment of cancer Chemistry; Metallurgy 0 Active
US11958892B2 Use of ICOS-based cars to enhance antitumor activity and car persistence Chemistry; Metallurgy 0 Active
US12234274B2 Use of the CD2 signaling domain in second-generation chimeric antigen receptors Chemistry; Metallurgy 0 Active
US12350334B2 Compositions and methods for generating a persisting population of T cells useful for the treatment of cancer Chemistry; Metallurgy 0 Active
US11718685B2 Compositions and methods for targeting stromal cells for the treatment of cancer Chemistry; Metallurgy 0 Active

Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.